- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01513811
Itopride as an Adjuvant for Bowel Preparation in Patients With Chronic Constipation is Effective
April 17, 2012 updated by: Xiaobo Li, Shanghai Jiao Tong University School of Medicine
High Dose of Itopride: a Valid Adjuvant for Bowel Preparation in Patients With Chronic Constipation
Bowel preparation is a major determinant of colonoscopy and colorectal surgery.
Polyethylene glycol electrolyte solutions (PEG-E) are the most commonly used laxatives in China.
However, a significant number of patients, especially those constipated patients, failed colonoscopies due to poor bowel cleaning.
Inadequate preparation may also lead to missed colonic lesions.
The study is based on the hypothesis: itopride hydrochloride, a prokinetic agent, its dual role as dopamine D2 receptor antagonism and acetylcho-linesterase inhibition make it an appropriate adjuvant for bowel preparation.
It was reported to promote colonic peristalsis, shorten colonic transit time and accelerate propulsion of colonic luminal contents through inhibition of M3 receptor and dopamine D2 receptors in vitro and in vivo.
So this study is to determine the efficacy, tolerance and safety of high dose of itopride, when given in different times before administration of PEG-E, for colonic preparation in patients with chronic constipation.
Study Overview
Status
Completed
Conditions
Detailed Description
Colonoscopy is a reliable procedure for the investigation of colonic and distal terminal ileum disease.
The diagnostic accuracy of colonoscopy is dependent on visualization of the colonic mucosa; hence an appropriate bowel preparation is essential for the examination.
Despite multiple lavage were used throughout the years, the suboptimal cleaning level have been reported vary from 10% to more than 20% and up to one-third of incomplete or failed colonoscopies can be ascribed to poor bowel preparation.
So it is important for us to search a new regimen for bowel preparation.
Study Type
Interventional
Enrollment (Actual)
115
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200001
- Shanghai Jiao-Tong University School of Medicine Renji Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients suspected colonic disease and suffered from chronic constipation were referred for colonoscopy and enrolled in the study. Chronic constipation was diagnosed on the basis of Rome III criteria.Suspected colonic disease was defined as:
- recent change of bowel habits;
- obscure GI bleeding (hemafecia, melena or positive fecal occult blood test);
- obscure abdominal pain;
- weight loss;
- positive findings in the colon on GI imaging;
- serological test referred to colorectal cancer such as CEA elevated obviously;
- family history of colorectal cancer or adenomatous polyps.
Exclusion Criteria:
- usage of prokinetic agents such as itopride, mosapride within 4 weeks and tricyclic antidepressants 8 weeks prior to entering the protocol;
- known allergies or other contraindication to PEG or itopride;
- a history of abdominal surgery or bowel obstruction;
- pregnant or lactating;
- conditions associated with severe cardiac, hepatic, or renal impairment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: group PEG
This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
|
Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water.
Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
Other Names:
|
Active Comparator: group PEG+Itp
Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
|
Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E).
PEG-E was dissolved in 2 L of water.
Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.
6 hours later, the colonoscopy was performed.
Other Names:
|
Active Comparator: group PEG+4Itp
Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
|
Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water.
Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours.
6 hours later, the colonoscopies were performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the quality of bowel preparation
Time Frame: the day of colonoscopy examination
|
the Boston Bowel Preparation Scale (BBPS): the colon was divided into 3 broad segments: the right side (the cecum and ascending colon), the middle section (the hepatic flexures, transverse colon and splenic flexures), and the left side of the colon (the descending colon, sigmoid colon, and rectum).
Each region of the colon receives a score from 0 to 3 as summarized in table 1, score 0 was considered poor preparation while score 3 indicated good cleaning quality.
And these segment scores are summed for a total BBPS score ranged from 0 to 9.
|
the day of colonoscopy examination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intestinal bubble scale
Time Frame: the day of colonoscopy examination
|
The scores of intestinal bubble were categorized into three levels: 0, no or nearly no bubble present; 1, small amounts of bubbles that could be washed away easily; 2, multiple collections of bubbles that could be washed away with volumes of water.
|
the day of colonoscopy examination
|
time of examination
Time Frame: the day of examination
|
Time of examination includes caecal intubation time and withdrawal time.
Caecal intubation time defined as the time passing the colonoscope to the ileocaecal valve.
Withdrawal time defined as the time withdrawing from ileocaecal junction to anus.
|
the day of examination
|
times of defecation
Time Frame: the day before and the day of examination
|
The times of defecation during the preparation were obtained and analyzed.
|
the day before and the day of examination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Li X B, M.D., Ph.D., Shanghai Jiao-Tong University School of Medicine Renji Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Actual)
November 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
January 16, 2012
First Submitted That Met QC Criteria
January 19, 2012
First Posted (Estimate)
January 20, 2012
Study Record Updates
Last Update Posted (Estimate)
April 19, 2012
Last Update Submitted That Met QC Criteria
April 17, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- rjyyxhk0906
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
Clinical Trials on Polyethylene glycol electrolyte solutions
-
University of OklahomaCompletedDiabetes MellitusUnited States
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
University of Texas Southwestern Medical CenterCompletedHepatic Encephalopathy | Cirrhosis | Portosystemic Encephalopathy | PSEUnited States
-
Orion Corporation, Orion PharmaCompleted
-
Changhai HospitalUnknownAdenoma Detection Rate | Bowel Preparation ScaleChina
-
Medical University of WarsawCompletedChildren Prior to ColonoscopyPoland
-
Nova Scotia Health AuthorityWithdrawnNerve Injury | Peripheral Nerve Injury
-
Cook County HealthCompletedBowel Preparation for ColonoscopyUnited States
-
Cleveland Clinic FloridaCompletedColon CancerUnited States
-
Oregon Health and Science UniversityUnknownColonoscopyUnited States